Evidence map›Paper›PMID 27036037›Full record

ArticleOncotarget2016

Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.

Preety Bajwa, Prathima B Nagendra, Sarah Nielsen, Subhransu S Sahoo, Amanda Bielanowicz, Janine M Lombard, J Erby Wilkinson, Richard A Miller, Pradeep S Tanwar

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Preety BajwaGynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, New South Wales, Australia.
Prathima B NagendraGynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, New South Wales, Australia.
Sarah NielsenHunter Cancer Biobank, New South Wales, Australia.
Subhransu S SahooGynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, New South Wales, Australia.
Amanda BielanowiczGynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, New South Wales, Australia.
Janine M LombardSchool of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
J Erby WilkinsonUnit for Laboratory Animal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Richard A MillerDepartment of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI, USA.
Pradeep S TanwarGynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, New South Wales, Australia.
Australia New Zealand Gynaecological Oncology Group · AUUniversity of Michigan–Ann Arbor · USCalvary Mater Newcastle Hospital · AU

Funding

Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
Laboratory for Anti-Geric Testing, Evaluation and ResearchU01AG022303 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RICHARD A MILLER · 2003 to 2026
$25.4M
NIA NIH HHS P30 AG024824NIA NIH HHS U01 AG022303
6 · The paper itself

Abstract

Ovarian cancer is a disease of older women. However, the molecular mechanisms of ovarian aging and their contribution to the pathogenesis of ovarian cancer are currently unclear. mTOR signalling is a major regulator of aging as suppression of this pathway extends lifespan in model organisms. Overactive mTOR signalling is present in up to 80% of ovarian cancer samples and is associated with poor prognosis. This study examined the role of mTOR signalling in age-associated changes in ovarian surface epithelium (OSE). Histological examination of ovaries from both aged mice and women revealed OSE cell hyperplasia, papillary growth and inclusion cysts. These pathological lesions expressed bonafide markers of ovarian cancer precursor lesions, Pax8 and Stathmin 1, and were presented with elevated mTOR signalling. To understand whether overactive mTOR signalling is responsible for the development of these pathological changes, we analysed ovaries of the Pten trangenic mice and found significant reduction in OSE lesions compared to controls. Furthermore, pharmacological suppression of mTOR signalling significantly decreased OSE hyperplasia in aged mice. Treatment with mTOR inhibitors reduced human ovarian cancer cell viability, proliferation and colony forming ability. Collectively, we have established the role of mTOR signalling in age-related OSE pathologies and initiation of ovarian cancer.

Indexed as

AgingAnimalsBlotting, WesternCell Line, TumorCell SurvivalEpithelial CellsEpitheliumFemaleHumansHyperplasiaImmunosuppressive AgentsMice, Inbred C57BLMice, TransgenicOvaryPTEN PhosphohydrolaseSirolimusImmunosuppressive AgentsPTEN PhosphohydrolaseSirolimusTOR Serine-Threonine KinasesGerotargetmTOROSEovarian agingovaryrapamycin

Identifiers

PMID27036037
PMCPMC4991377
OpenAlexW2323847176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.